A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein

Trial Profile

A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs ALRN 6924 (Primary)
  • Indications Carcinoma; Haematological malignancies; Peripheral T-cell lymphoma; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms All-comers
  • Sponsors Aileron Therapeutics
  • Most Recent Events

    • 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
    • 10 Aug 2017 According to an Aileron Therapeutics media release, interim results from phase 2a part of this trial is expected in the first half of 2018.
    • 03 Jun 2017 Results (n = 41) published in an Aileron Therapeutics media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top